History of autoimmune conditions and lymphoma prognosis

Geffen Kleinstern; Matthew J Maurer; Mark Liebow; Thomas M Habermann; Jean L Koff; Cristine Allmer; Thomas E Witzig; Grzegorz S Nowakowski; Ivana N Micallef; Patrick B Johnston; David J Inwards; Carrie A Thompson; Andrew L Feldman; Brian K Link; Christopher Flowers; Susan L Slager; James R Cerhan

doi:10.1038/s41408-018-0105-4

Back

History of autoimmune conditions and lymphoma prognosis

Journal article

Open access

Peer reviewed

History of autoimmune conditions and lymphoma prognosis

Geffen Kleinstern, Matthew J Maurer, Mark Liebow, Thomas M Habermann, Jean L Koff, Cristine Allmer, Thomas E Witzig, Grzegorz S Nowakowski, Ivana N Micallef, Patrick B Johnston, …

Blood cancer journal (New York), Vol.8(8), 73

08/01/2018

DOI: 10.1038/s41408-018-0105-4

PMCID: PMC6070501

PMID: 30069001

Files and links (1)

url

https://doi.org/10.1038/s41408-018-0105-4View

Published (Version of record) Open Access

Abstract

Autoimmune conditions are strong risk factors for developing lymphoma, but their role in lymphoma prognosis is less clear. In a prospective cohort study, we evaluated self-reported history of eight autoimmune conditions with outcomes in 736 diffuse large B-cell, 703 follicular, 302 marginal zone (MZL), 193 mantle cell (MCL), 297 Hodgkin lymphoma (HL), and 186 T-cell lymphomas. We calculated event-free survival (EFS) and overall survival (OS), and estimated hazard ratios (HRs) and 95% confidence intervals (CIs), adjusting for sex, prognostic score, and treatment. History of any of the eight autoimmune conditions ranged from 7.4% in HL to 18.2% in MZL, and was not associated with EFS or OS for any lymphoma subtype. However, there was a positive association of autoimmune conditions primarily mediated by B-cell responses with inferior EFS in MCL (HR = 2.23, CI: 1.15-4.34) and HL (HR = 2.63, CI: 1.04-6.63), which was largely driven by rheumatoid arthritis. Autoimmune conditions primarily mediated by T-cell responses were not found to be associated with EFS or OS in any lymphoma subtype, although there were few events for this exposure. Our results indicate that distinguishing autoimmune conditions primarily mediated by B-cell/T-cell responses may yield insight regarding the impact of this comorbid disease, affecting ~10% of lymphoma patients, on survival.

Details

Title: Subtitle: History of autoimmune conditions and lymphoma prognosis
Creators: Geffen Kleinstern - Mayo Clinic
Matthew J Maurer - Mayo Clinic
Mark Liebow - Mayo Clinic
Thomas M Habermann - Mayo Clinic
Jean L Koff - Emory University
Cristine Allmer - Mayo Clinic
Thomas E Witzig - Mayo Clinic
Grzegorz S Nowakowski - Mayo Clinic
Ivana N Micallef - Mayo Clinic
Patrick B Johnston - Mayo Clinic
David J Inwards - Division of Hematology, Mayo Clinic, Rochester, USA,
Carrie A Thompson - Mayo Clinic
Andrew L Feldman - Mayo Clinic
Brian K Link - University of Iowa
Christopher Flowers - Emory University
Susan L Slager - Mayo Clinic
James R Cerhan - Mayo Clinic
Resource Type: Journal article
Publication Details: Blood cancer journal (New York), Vol.8(8), 73
DOI: 10.1038/s41408-018-0105-4
PMID: 30069001
PMCID: PMC6070501
NLM abbreviation: Blood Cancer J
ISSN: 2044-5385
eISSN: 2044-5385
Grant note: U01 CA195568 / NCI NIH HHS P30 CA086862 / NCI NIH HHS P50 CA097274 / NCI NIH HHS
Language: English
Date published: 08/01/2018
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Internal Medicine
Record Identifier: 9984359585402771

Metrics

75 Record Views

32 Times Cited - Web of Science